Armendariz E, Chelluri L, Ptachcinski R
Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh School of Medicine, PA.
Crit Care Med. 1990 Jun;18(6):675-6. doi: 10.1097/00003246-199006000-00023.
We studied the pharmacokinetics of amikacin in a patient with acute oliguric renal failure during continuous veno-venous hemofiltration (CVVH). The volume of distribution, terminal disposition rate constant and elimination half-life for amikacin were 27.9 L, 0.023.h-1 and 29.7 h, respectively. Total body clearance for amikacin was 10.54 ml/min and CVVH clearance was 10.11 ml/min. Sieving coefficient for amikacin was 0.93 +/- 0.16. Our data show that during CVVH at a filtration rate of 10 ml/min, the clearance of amikacin is similar to that reported in patients with renal failure who are not being treated with CVVH.
我们研究了在持续静脉-静脉血液滤过(CVVH)期间急性少尿性肾衰竭患者中阿米卡星的药代动力学。阿米卡星的分布容积、终末处置速率常数和消除半衰期分别为27.9 L、0.023 h⁻¹和29.7 h。阿米卡星的总体清除率为10.54 ml/min,CVVH清除率为10.11 ml/min。阿米卡星的筛系数为0.93±0.16。我们的数据表明,在滤过率为10 ml/min的CVVH期间,阿米卡星的清除率与未接受CVVH治疗的肾衰竭患者中报道的清除率相似。